Keywords , weight loss , liver fibrosis , phase 3 clinical trial , metabolic syndrome , non-invasive tests 0 1 INTRODUCTION Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of chronic liver disease worldwide, tightly linked to obesity, type 2 diabetes mellitus (T2DM), and other components of the metabolic syndrome [1]
Heinemann L, Parkin CG (2018) Rethinking the viability and utility of inhaled insulin in clinical practice
The major limitations of this trial are the small sample size and the limited generalisability of the results due to the short duration and the population of healthy subjects
doi: 10.2337/db15-0436 60 TsaiSWinerSWinerDA
Using nuclear magnetic resonance (NMR) spectroscopy, Smeland and colleagues also demonstrated increased levels of norepinephrine and serotonin in the cortex of healthy mice, after 25 days of treatment with acetylcarnitine at a daily dose of approximately 0.5 g/kg body weight [117]
About an hour later, Mueller said he turned to his wife with a reaction he still remembers
